Immune-mediated Modulation of Breast Cancer Growth and Metastasis by the Chemokine Mig (CXCL9) in a Murine Model
暂无分享,去创建一个
Xinrong Ma | R. Dorsey | Tonya C. Walser | O. Goloubeva | A. Fulton | T. Walser | N. Kundu
[1] Michael G. Johnson,et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. , 2006, Cancer research.
[2] R. Strieter,et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2006, Cancer research.
[3] M. Burdick,et al. CXCR3/CXCR3 Ligand Biological Axis Impairs RENCA Tumor Growth by a Mechanism of Immunoangiostasis1 , 2006, The Journal of Immunology.
[4] J. Blay,et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner , 2005, The Journal of experimental medicine.
[5] P. Hensbergen,et al. The CXCR3 Targeting Chemokine CXCL11 Has Potent Antitumor Activity In Vivo Involving Attraction of CD8+ T Lymphocytes But Not Inhibition of Angiogenesis , 2005, Journal of immunotherapy.
[6] Xinrong Ma,et al. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease , 2005, Cancer Immunology, Immunotherapy.
[7] B. Quesnel,et al. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. , 2005, Blood.
[8] S. Horita,et al. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. , 2004, The Journal of urology.
[9] M. Huang,et al. EBV-Induced Molecule 1 Ligand Chemokine (ELC/CCL19) Promotes IFN-γ-Dependent Antitumor Responses in a Lung Cancer Model , 2003, The Journal of Immunology.
[10] M. Huang,et al. Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2003, Human gene therapy.
[11] M. Tagawa,et al. Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects. , 2003, Oncology reports.
[12] M. Huang,et al. SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10 , 2003, Molecular Cancer.
[13] J. Xiang,et al. Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors , 2002, Cancer Gene Therapy.
[14] C. Tannenbaum,et al. Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. , 2002, Cancer research.
[15] J. Xiang,et al. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. , 2002, Cellular immunology.
[16] A. Feldman,et al. Retroviral gene transfer of interferon‐inducible protein 10 inhibits growth of human melanoma xenografts , 2002, International journal of cancer.
[17] N. Giese,et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice , 2002, Cancer Gene Therapy.
[18] Y. Ba,et al. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. , 2001, Cancer research.
[19] R. Strieter,et al. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2001, Cancer research.
[20] G. Gaedicke,et al. IFN-γ-Inducible Protein-10 Is Essential for the Generation of a Protective Tumor-Specific CD8 T Cell Response Induced by Single-Chain IL-12 Gene Therapy1 , 2001, The Journal of Immunology.
[21] R. Dorsey,et al. Expression of the Chemokines IP-10 and Mig in IL-10 Transduced Tumors , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.
[22] M. Hitt,et al. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity , 2001, Gene Therapy.
[23] M. Burdick,et al. Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo1 , 2000, The Journal of Immunology.
[24] J. Murray,et al. Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[25] J. Prieto,et al. Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy1 , 2000, The Journal of Immunology.
[26] M. Iannettoni,et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. , 2000, Human gene therapy.
[27] E. Bröcker,et al. Strong expression of the lymphoattractant C‐X‐C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma , 1999, The Journal of pathology.
[28] T. Olencki,et al. Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma , 1999 .
[29] A. Fulton,et al. Interleukin‐10 gene transfer activates interferon‐γ and the interferon‐γ‐inducible genes Gbp‐1/Mag‐1 and Mig‐1 in mammary tumors , 1999 .
[30] J. Teruya-Feldstein,et al. Contribution of the CXC chemokines IP‐10 and Mig to the antitumor effects of IL‐12 , 1998, Journal of leukocyte biology.
[31] R. Strieter,et al. Tumor angiogenesis is regulated by CXC chemokines. , 1998, The Journal of laboratory and clinical medicine.
[32] J. Finke,et al. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.
[33] James G. Boyd,et al. Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.
[34] F. Balkwill,et al. Multiple molecular and cellular changes associated with tumour stasis and regression during IL‐12 therapy of a murine breast cancer model , 1998, International journal of cancer.
[35] J. Teruya-Feldstein,et al. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo , 1997 .
[36] J. Farber. Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.
[37] L. Koniaris,et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. Whyte,et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases , 1996, The Journal of experimental medicine.
[39] Simon A. Jones,et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.
[40] J. Finke,et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. , 1996, Journal of immunology.
[41] P. Leder,et al. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo , 1993, The Journal of experimental medicine.
[42] H. Land,et al. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.
[43] D. Dexter,et al. Heterogeneity of tumor cells from a single mouse mammary tumor. , 1978, Cancer research.
[44] P. Sinha,et al. Tumor-Associated Myeloid-Derived Suppressor Cells , 2007 .
[45] E. Jaffee,et al. Cancer Immunotherapy : Immune Suppression and Tumor Growth , 2007 .
[46] F. Miller,et al. From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae. , 2004, Breast disease.
[47] T. Olencki,et al. Interferon-g and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma , 1999 .